- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Tahir Amin: Patent Opposition and Patient Access to High-Cost Drugs
Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses the role of patent opposition in giving patients access to high-cost drugs.
Transcript:
How did you decide to focus on HIV drugs for your work in patent opposition?
At the time, around 2000, there was this massive uproar by basically people in the developing world who didn’t have access to affordable HIV drugs. I think the prices were around $2000 to $10,000. Then there was a case brought by 40 pharmaceutical companies against the South African government at the time, and out of that grew this access to medicine movement.
At the time, this was basically trying to get cheaper, affordable HIV drugs to low-income people in developing countries. In India, at the time, it was bringing in its new patent law in 2005 and everyone was concerned. Doctors Without Borders was concerned, and called India the “pharmacy of the poor” because it was supplying so much of the HIV medicine, and they were concerned this pipeline would dry up due to patents being granted.
So, we focused on HIV largely because of that movement, and even today, despite all the great work that’s been done, we’re seeing it’s still a problem. I think recently there was an article saying the number of people getting HIV medicines in the [United States] is not as high as it should be. There’s actually going to be a crisis in the middle-income countries in 2020, and a number of people won’t be able to get HIV treatment. So, there’s still so much more to do and the HIV issue is still central to our work despite almost 10 years of the work we started back then.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
